Kura Oncology, Inc. (KURA)
$9.83-5.48%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $873M
- Beta
- 0.38
- P/E (TTM)
- -2.92
- Short % float
- 16.77%
- Days to cover
- 7.7
- SI change
- -2.7%
- 1W
- -6.65%
- 1M
- -14.97%
- vs SPY 1W
- -7.07%
- vs SPY 1M
- -17.03%
Industry peers
FMP comparable companies · ranked by market cap
- HCMSELLHUTCHMED (China) Limited$2.5BRECOVERYQ 5$14.10-1.32%
- NRIXSELLNurix Therapeutics, Inc.$2.3BBEARQ 11$22.35-0.14%
- SLSSELLSELLAS Life Sciences Group, Inc.$2.2BRECOVERYQ -9$11.65+4.02%
- SNDXSELLSyndax Pharmaceuticals, Inc.$1.5BCRISISQ 16$16.99-15.71%
- ORICSELLORIC Pharmaceuticals, Inc.$1.2BBEARQ 3$11.99-4.23%
- TYRASELLTyra Biosciences, Inc.$1.2BCRISISQ 5$19.94-5.31%
- RIGLBUYRigel Pharmaceuticals, Inc.$908MBULLQ 9$49.08-3.42%
- VSTMBUYVerastem, Inc.$736MRECOVERYQ 4$8.38-9.70%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on KURA?
- LOPJLB’s latest quantitative signal on Kura Oncology, Inc. (KURA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is KURA in?
- Kura Oncology, Inc. (KURA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Kura Oncology, Inc. (KURA) do?
- Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The companyâs first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted the…